TY - JOUR
T1 - The effects of melatonin administration on disease severity and sleep quality in children with atopic dermatitis
T2 - A randomized, double-blinded, placebo-controlled trial
AU - Taghavi Ardakani, Abbas
AU - Farrehi, Maryam
AU - Sharif, Mohammad Reza
AU - Ostadmohammadi, Vahidreza
AU - Mirhosseini, Naghmeh
AU - Kheirkhah, Davood
AU - Moosavi, Seyed Gholam Abbas
AU - Behnejad, Milad
AU - Reiter, Russel J.
AU - Asemi, Zatollah
N1 - Publisher Copyright:
© 2018 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.
PY - 2018/12
Y1 - 2018/12
N2 - Background: The aim of this clinical trial was to determine the effects of melatonin administration on disease severity and sleep quality in children diagnosed with atopic dermatitis (AD). Methods: This randomized, double-blinded, placebo-controlled trial was conducted by recruiting 70 patients, aged 6-12 years, who had been diagnosed with AD. Study participants were randomly allocated into two intervention groups to receive either 6 mg/d melatonin supplements or placebo (n = 35 each group) for 6 weeks. Severity of disease was assessed using the scoring atopic dermatitis (SCORAD) and objective SCORAD indices. Sleep quality was evaluated by completing the Children's Sleep Habits Questionnaire (CSHQ). Results: Following 6 weeks of intervention, melatonin supplementation significantly improved SCORAD index (β −3.55; 95% CI, −6.11, −0.98; P = 0.007), objective SCORAD index (β −3.23; 95% CI, −5.08, −1.38; P = 0.001), serum total IgE levels (β −153.94 ku/L; 95% CI, −260.39, −47.49; P = 0.005), and CSHQ scores (β −2.55; 95% CI, −4.34, −0.75; P = 0.006). However, melatonin had no significant impact on pruritus scores, high-sensitivity C-reactive protein (hs-CRP), sleep-onset latency, total sleep time, weight, and BMI compared with placebo. Conclusions: Overall, melatonin supplementation had beneficial effects on disease severity, serum total IgE levels, and CSHQ among children diagnosed with AD.
AB - Background: The aim of this clinical trial was to determine the effects of melatonin administration on disease severity and sleep quality in children diagnosed with atopic dermatitis (AD). Methods: This randomized, double-blinded, placebo-controlled trial was conducted by recruiting 70 patients, aged 6-12 years, who had been diagnosed with AD. Study participants were randomly allocated into two intervention groups to receive either 6 mg/d melatonin supplements or placebo (n = 35 each group) for 6 weeks. Severity of disease was assessed using the scoring atopic dermatitis (SCORAD) and objective SCORAD indices. Sleep quality was evaluated by completing the Children's Sleep Habits Questionnaire (CSHQ). Results: Following 6 weeks of intervention, melatonin supplementation significantly improved SCORAD index (β −3.55; 95% CI, −6.11, −0.98; P = 0.007), objective SCORAD index (β −3.23; 95% CI, −5.08, −1.38; P = 0.001), serum total IgE levels (β −153.94 ku/L; 95% CI, −260.39, −47.49; P = 0.005), and CSHQ scores (β −2.55; 95% CI, −4.34, −0.75; P = 0.006). However, melatonin had no significant impact on pruritus scores, high-sensitivity C-reactive protein (hs-CRP), sleep-onset latency, total sleep time, weight, and BMI compared with placebo. Conclusions: Overall, melatonin supplementation had beneficial effects on disease severity, serum total IgE levels, and CSHQ among children diagnosed with AD.
KW - atopic dermatitis
KW - disease severity
KW - melatonin
KW - sleep quality
UR - http://www.scopus.com/inward/record.url?scp=85053934584&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85053934584&partnerID=8YFLogxK
U2 - 10.1111/pai.12978
DO - 10.1111/pai.12978
M3 - Article
C2 - 30160043
AN - SCOPUS:85053934584
VL - 29
SP - 834
EP - 840
JO - Pediatric Allergy and Immunology
JF - Pediatric Allergy and Immunology
SN - 0905-6157
IS - 8
ER -